POLARIS program, launched in 2024 to evaluate ETX101 for SCN1A+ Dravet syndrome, is ongoing. Expect to complete dosing and share preliminary safety and efficacy data in 2H25. ETX201 gene therapy ...
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D toward its Dravet syndrome program. The asset in question, dubbed ...
Encoded Therapeutics is joining the ranks of biotechs pummeled by the whiplash of a difficult biotech market, laying off "close to 10%" of its team, according to Chief Business Officer David McNinch.
ORLANDO, Fla.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, announced today that ...
Forty trillion is the kind of number that gives one pause. Consider it written out with its 13 zeros: 40,000,000,000,000. Assembling and maintaining a collection of 40 trillion of anything seems like ...
AAV9-based Angelman Syndrome candidate, ETX201, demonstrates safety and target engagement in non-human primates (NHPs), with unsilencing of UBE3A across disease-relevant brain regions Multiple ...
Following our sold-out show with Frantic, we're back and taking over the entire Tunnel Club once again-this time even bigger! We all know Hard Housers love to dress up - and at Encoded, we're bringing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback